Skip to main content

Part of UT Health San Antonio

Profiles - UT Health San AntonioProfiles - UT Health Science Center San Antonio

Part of UT Health San Antonio

Menu
  • Home

You are here

  • Profiles Home
  • Faculty Directory
  • Daruka Mahadevan
Daruka Mahadevan

Programs

  • M.D./Ph.D. in South Texas Medical Scientist Training Program
  • Ph.D. in Integrated Biomedical Sciences

Departments & Divisions

  • Department of Medicine
  • Division of Hematology & Oncology

Institutes & Centers

  • Mays Cancer Center

Daruka Mahadevan, MD, PhD

Division Chief, Hematology and Medical Oncology

Professor of Medicine

I am an internationally recognized Physician-Scientist in Hematology and Medical Oncology. I have a demonstrated track record of delivering first-in-human investigational agents to cancer patients.  In addition, I have successfully directed a structure-based translational drug discovery laboratory program with the award of 9 individual US patents for new drugs in oncology. One drug ‘Amuvatinib’ targeting c-Kit/c-Met/PDGFR/RAD51 has completed phase I and II trials. As PI or co-PI on several NIH and Foundation grants, I established proof-of-concept and delivered on drug discovery - R01 (AKT PH domain inhibitors) and on drug development - NSF (Prostate cancer translational drug development), SPORE in Lymphoma (Aurora kinase inhibitor therapy for aggressive lymphoma) and SWOG Hope Foundation (targeted therapeutics for aggressive B- and T-cell non-Hodgkin Lymphomas). Over the past 4 years (2016 to 2019) at the University of Arizona Cancer Center, an NCI designated Comprehensive Cancer Center, as part of the Cancer Center Support Grant (CCSG), I was the co-chair of the Therapeutic Development Program (TDP) that fostered collaboration among participant members from the Cancer Center with monthly meetings, hosted the yearly Cancer Center retreat in 2016 and collaborative day of research with the Cancer Biology Program. In addition, I participated in the monthly Scientific Leadership committee meetings at UACC, the NCI external advisory board (EAB) meeting (Feb 2016, CCSG renewal) and yearly EAB meetings. In addition, I received an NCI P30 supplement (2017-2019) of $150,000 to study rare cancers by whole exome sequencing of tumor vs. normal in collaboration with the UA Genomics Core. We have sequenced over 40 patients with a multitude of rare cancers and presented this data at ASCO 2019. A manuscript is in preparation for peer-review. At UTHSA, as Division Chief in Hematology/Medical Oncology, I will continue increase and expand the bandwidth of the early phase therapeutics portfolio to also include Investigator Initiated Studies and help Dr. Ruben Mesa, the Cancer Center Director with his vision for the Mays Cancer Center.

map image

UT Health San Antonio

7703 Floyd Curl Drive
San Antonio, TX 78229

210-567-7000

We make lives better ©

We're a part of UT Health San Antonio, provider of comprehensive health,  dental, &  cancer care,  advanced academics,  and  life-saving research.

Web Privacy | Links from websites affiliated with The University of Texas Health Science Center at San Antonio's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.